Publicaciones seleccionadas
- Santana-Hernández S, Suárez J, Servitja S, Berenguer-Molins P, Costa-Garcia M, Comerma L, Rea A, Perera J, Menéndez S, Arpí O, Bermejo B, Martínez-Larrad MT, Cejalvo JM, Comino-Méndez I, Pascual J, Alba E, López-Botet M, Rojo F, Rovira A, Albanell J, Muntasell A*. NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer. J Exp Clin Canc Res 2024; 43(1): 10.
- López-Botet M*, De María A, Muntasell A, Della Chiesa M, Vilches C. Adaptive NK cell response to human cytomegalovirus: Facts and open issues. Semin Immunol 2023; 65: 101706.
- Cabo M, Santana-Hernández S, Costa-Garcia M, Rea A, Lozano-Rodríguez R, Ataya M, Balaguer F, Juan M, Ochoa MC, Menéndez S, Comerma L, Rovira A, Berraondo P, Albanell J, Melero I, López-Botet M, Muntasell A. CD137 costimulation counteracts TGF? inhibition of NK-cell antitumor function. Cancer Immunol Res 2021; 9(12): 1476-1490.
- Muntasell A*, Servitja S, Cabo M, Bermejo B, Perez-Buira S, Rojo F, Costa-Garcia M, Arpí O, Moraru M, Serrano L, Tusquets I, Martínez MT, Heredia G, Vera A, Martínez-García M, Soria L, Comerma L, Santana-Hernández S, Eroles P, Rovira A, Vilches C, Lluch A, Albanell J*, López-Botet M. High numbers of circulating CD57+ NK cells associate with resistance to HER2-specific therapeutic antibodies in HER2+ primary breast cancer. Cancer Immunol Res 2019; 7(8): 1280-1292.
- Ochoa MC, Perez-Ruiz E, Minute L, Oñate C, Perez G, Rodríguez I, Zabaleta A, Alignani D, Fernandez-Sendin M, Lopez A, Muntasell A, Sanmamed MF, Paiva B, López-Botet M, Berraondo P, Melero I*. Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells. OncoImmunology 2019; 8(7): 1599636.
- Muntasell A*, Rojo F, Servitja S, Rubio-Perez C, Cabo M, Tamborero D, Costa-Garcia M, Martínez-García M, Menéndez S, Vazquez I, Lluch A, Gonzalez-Perez A, Rovira A, López-Botet M, Albanell J*. NK cell infiltrates and HLA class I expression in primary HER2+ breast cancer predict and uncouple pathological response and disease-free survival. Clin Cancer Res 2019; 25(5): 1535-1545.
- Costa-García M, Ataya M, Moraru M, Vilches C, López-Botet M, Muntasell A*. Human Cytomegalovirus Antigen Presentation by HLA-DR+ NKG2C+ Adaptive NK Cells Specifically Activates Polyfunctional Effector Memory CD4+ T Lymphocytes. Front Immunol 2019; 10: 687.
- Tamborero D*, Rubio-Perez C, Muiños F, Sabarinathan R, Piulats JM, Muntasell A, Dienstmann R, López-Bigas N, Gonzalez-Perez A*. A pan-cancer landscape of interactions between solid tumors and infiltrating immune cell populations. Clin Cancer Res 2018; 24(15): 3717-3728.
- Cabo M, Offringa R, Zitvogel L, Kroemer G, Muntasell A*, Galluzzi L*. Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. OncoImmunology 2017; 6(12): e1371896.
- Sabbaghi MA, Gil-Gómez G, Guardia C, Servitja S, Arpí O, García-Alonso S, Menéndez S, Arumí M, Serrano L, Salido M, Muntasell A, Martínez-García M, Zazo S, Chamizo C, González-Alonso P, Madoz-Gúrpide J, Eroles P, Arribas J, Tusquets I, Lluch A, Pandiella A, Rojo F, Rovira A, Albanell J*. Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer. Clin Cancer Res 2017; 23(22): 7006-7019.
- Muntasell A*, Cabo M, Servitja S, Tusquets I, Martínez-García M, Rovira A, Rojo F, Albanell J, López-Botet M. Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. Front Immunol 2017; 8: 1544.
- López-Montañés M, Alari E, Sintes J, Martínez-Rodríguez JE, Muntasell A*, López-Botet M*. Antibody-Dependent NK Cell Activation Differentially Targets EBV-Infected Cells in Lytic Cycle and Bystander B Lymphocytes Bound to Viral Antigen-Containing Particles. J Immunol 2017; 199(2): 656-665.
- Muntasell A, Ochoa MC, Cordeiro L, Berraondo P, López-Díaz de Ceiro A, Cabo M, López-Botet M, Melero I*. Targeting NK-cell checkpoints for cancer immunotherapy. Curr Opin Immunol 2017; 45: 73-81.
